IMU imugene limited

18.2%

1.3¢

It's a shit announcement. Nothing new in here. Management is...

First 74 Last

Share
Profile

Follow
Single

242 Posts.

74

01/05/25

18:25

Post #: 78884944
Share

Originally posted by Martin288: ↑

Been here ten years.
Good to see a letter.
I interprete it as IMU say;

1. No real results planned for 2 years.
2. Board has no control over current share price - Not true
3. Salaries - there is some misinformation here about salaries being necessarily high due to market.s requiring IMU to pay higher salaries However, When LC started she started on about $340k. Its now over $2m and her salary increased due to share price rising. Salary was set on share performance not what market would pay. The market has not said LC is worth 7 times more now. The share price has gone down but salary stays same. The remuneration committee and the second strike on a NO vote for remuneration could see board spill at next AGM.
Someone like Monil Shah was on over $800k a year and had no results in creating value.
Glover is on over $1.4.
Lets not mention the airport advertising .It strikes me as egos running wild at their own importance promoting all the wonderful work but nothing to show for it. Harsh but true.
The salaries cannot be justified given the funds available.

The costs are set at a $3b company and even directors salaries remain at the level of a $3b company. I think their egos are stuck on this myth but we are paying for it. This management is not worth what we are paying them as they have failed to deliver.

Trial time lines. - Time lines blew out as resources were spread too thin on too many prospective trials. Management must take responsibility for this. Its not true that trials are just expensive as an excuse. Its complete mismanagement. IMHO The time lines were flawed and were made optimistic for IMU benefit to entice more retail investors to pump share price. Now that air is out of share price balloon, truth comes out and now Hopper is cutting and running from retailers and onto Institutional investors .`
IMU management knew that before they started how long trials will take on rare diseases .This is all within management control.

I recall the exuberance of buying a manufacturing facility in North Carolina only to divest themselves of it six months later and try and now sell it to shareholders as a somehow well managed cost reduction when all it was was a stuff up of huge financial proportions.

There is a trait here IMU management should not be proud of. They are not taking responsibility for their actions including costs control and share price.

I do hope in the end IMU have some success. I have traded and invested in IMU for ten years now. This shareholder letter out of the blue is encouraging but does not plaster over poor management performance.

Good luck to all as we anticipate at least a USD $30m raise by year end with only 6 months cash left according to the quarterly.
I suspect a trail announcement for azercel on one hand with a cap in the other asking an Institutional to invest at a discount share price for PH mates to detriment of retail shareholders who got us this far.

Hope we get lucky and sell something to keep the lights on and share price increases a little. Otherwise noodles for Christmas dinner.

I am holding what I have and hanging on with my white knuckles for the ride. Good luck.

Expand

It's a shit announcement. Nothing new in here. Management is saying we don't know why the SP is getting beaten down.
We are not aiming for phase 3 for any of our products and we would likely do a license deal based on the 'wonderful data'
I don't know but a blind Freddy can also see that big pharma will eat IMU for breakfast one day at a very very cheap price!
PH once sold his company for 500ml, he won't be able to seal a deal this time is my view.
It's a losing battle.

IMU Price at posting: 2.4¢ Sentiment: Sell Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

First 74 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.3¢		Change 0.002(18.2%)		Mkt cap ! $97.07M

Open	High	Low	Value	Volume
1.2¢	1.4¢	1.1¢	$625.7K	50.56M

Buyers (Bids)

No.	Vol.	Price($)
20	5795292	1.2¢

Sellers (Offers)

Price($)	Vol.	No.
1.3¢	3258567	9

View Market Depth

No.	Vol.	Price($)
18	5735292	0.012
35	10497532	0.011
118	35980571	0.010
37	19431668	0.009
13	4220748	0.008

Price($)	Vol.	No.
0.013	3078567	8
0.014	10063029	39
0.015	6593187	20
0.016	6224494	27
0.017	7006978	10

Last trade - 16.10pm 27/06/2025 (20 minute delay)

IMU (ASX) Chart

It's a shit announcement. Nothing new in here. Management is...

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Monash IVF shares cater 25% – Disaster or deep-value play?

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

It's a shit announcement. Nothing new in here. Management is...

Top Stories

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Monash IVF shares cater 25% – Disaster or deep-value play?

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News